Document is current
Any future updates will be listed below
-
Authors
Palikuqi, Brisa
Nguyen, Duc-Huy T.
Li, Ge
Schreiner, Ryan https://orcid.org/0000-0002-7457-6606
Pellegata, Alessandro F. https://orcid.org/0000-0002-5618-4641
Liu, Ying
Redmond, David
Geng, Fuqiang
Lin, Yang https://orcid.org/0000-0002-0709-2468
Gómez-Salinero, Jesus M. https://orcid.org/0000-0002-9024-2171
Yokoyama, Masataka
Zumbo, Paul
Zhang, Tuo https://orcid.org/0000-0001-5396-918X
Kunar, Balvir
Witherspoon, Mavee
Han, Teng
Tedeschi, Alfonso M.
Scottoni, Federico https://orcid.org/0000-0001-6796-7919
Lipkin, Steven M.
Dow, Lukas https://orcid.org/0000-0001-7048-1418
Elemento, Olivier
Xiang, Jenny Z.
Shido, Koji https://orcid.org/0000-0001-6303-3238
Spence, Jason R. https://orcid.org/0000-0001-7869-3992
Zhou, Qiao J.
Schwartz, Robert E.
De Coppi, Paolo https://orcid.org/0000-0002-1659-0207
Rabbany, Sina Y.
Rafii, Shahin
- License Information
-
More Information
Article History
Received: 6 December 2017
Accepted: 8 June 2020
First Online: 9 September 2020
Competing interests
: S.R. is the founder and a non-paid consultant to Angiocrine Bioscience. O.E. is a scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and One Three Biotech. R.E.S. is a scientific advisor and member of the SAB for Miromatrix Inc.
